SCHEMBL15859547

SCHEMBL15859547

[CH2]OC#CCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
TSHR P16473 3/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
CALM1 P0DP23 1/20 0.36
KCNH2 Q12809 2/20 0.36
IDO1 P14902 2/20 0.34
LOXL2 Q9Y4K0 1/20 0.33
AGXT P21549 1/20 0.33
TRPA1 O75762 1/20 0.33
ALDH1A1 P00352 1/20 0.33
DHFR P00374 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A3 Q01959 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9128675 0.81 TP53 (0.42) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL2557228 0.77 TP53 (0.44) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL7496556 0.77 IDO1 (0.44) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL3888886 0.77 CALM1 (0.50) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL29151789 0.76 TP53 (0.37) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL6075646 0.74 MAOB (0.39) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL15859286 0.74 FFAR1 (0.39) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL2987051 0.74 TP53 (0.46) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL1453870 0.73 CALM1 (0.41) TP53TSHRFFAR1FFAR4CALM1
SCHEMBL14775110 0.72 AKR1B1 (0.45) TSHRFFAR1FFAR4ALDH1A1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870661-B2 Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity SHIONOGI & CO., LTD. (JP) 2020-12-22 US disclosed
EP-2772480-B2 HIV REPLICATION INHIBITOR SHIONOGI & CO (JP) 2020-12-09 EP disclosed
EP-3670496-A2 ACC2 INHIBITORS Shionogi&Co., Ltd. (JP) 2020-06-24 EP disclosed
US-20200055873-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2020-02-20 US disclosed
EP-2952503-B1 CARBOXYLIC ACID DERIVATIVES AS HIV REPLICATION INHIBITOR SHIONOGI & CO (JP) 2019-10-23 EP disclosed
US-20190144396-A1 9-MEMBERED FUSED RING DERIVATIVE SHIONOGI & CO., LTD. (JP) 2019-05-16 US disclosed
US-10233156-B2 9-membered fused ring derivative SHIONOGI & CO., LTD. (JP) 2019-03-19 US disclosed
US-20180362543-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2018-12-20 US disclosed
US-10150728-B2 Alkylene derivatives SHIONOGI & CO., LTD. (JP) 2018-12-11 US disclosed
US-20180162876-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2018-06-14 US disclosed
EP-3059225-A1 NOVEL ALKYLENE DERIVATIVE Shionogi & Co., Ltd. (JP) 2016-08-24 EP disclosed
US-20150361093-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2015-12-17 US disclosed
EP-2952503-A1 HIV REPLICATION INHIBITOR Shionogi & Co., Ltd. (JP) 2015-12-09 EP disclosed
US-9199959-B2 HIV replication inhibitor SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE SHIONOGI & CO., LTD. (JP) 2015-09-03 US disclosed
US-20140316037-A1 BIODEGRADABLE ALIPHATIC-AROMATIC COPOLYESTERS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURE, AND ARTICLES THEREOF SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2014-10-23 US disclosed
US-20140275074-A1 HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY SHIONOGI & CO., LTD. (JP) 2014-09-18 US disclosed
US-20140249306-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2014-09-04 US disclosed
EP-2772480-A1 HIV REPLICATION INHIBITOR Shionogi & Co., Ltd. (JP) 2014-09-03 EP disclosed
EP-2752410-A1 HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY Shionogi & Co., Ltd. (JP) 2014-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275074-A1 HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY PTGDR, PTGDR2, PTGER4 TP53 4674/4885TSHR 499/4885FFAR1 291/4885
US-10150728-B2 Alkylene derivatives ACSS2, ACACB, CES2 TP53 4460/4885TSHR 1082/4885FFAR1 346/4885
US-20200055873-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY NR4A3, CCR3, NCOA3 TP53 2754/4885TSHR 2209/4885FFAR1 1909/4885
US-20150361093-A1 HIV REPLICATION INHIBITOR RTF2, REV1, PCNA TP53 2963/4885TSHR 4441/4885FFAR1 3186/4885
US-20180162876-A1 NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY NR4A3, CCR3, NCOA3 TP53 2754/4885TSHR 2209/4885FFAR1 1909/4885
US-20150246938-A1 NOVEL OLEFIN DERIVATIVE ACSS2, ACACB, ACAT2 TP53 4801/4885TSHR 2129/4885FFAR1 661/4885
US-10870661-B2 Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity NR4A3, CCR3, NCOA3 TP53 2754/4885TSHR 2209/4885FFAR1 1909/4885
US-20140249306-A1 HIV REPLICATION INHIBITOR SSU72, RTF2, ZC3HAV1 TP53 1890/4885TSHR 4140/4885FFAR1 2081/4885
US-20190144396-A1 9-MEMBERED FUSED RING DERIVATIVE ACSS2, AGTR2, ACSL3 TP53 4381/4885TSHR 2184/4885FFAR1 941/4885
US-10233156-B2 9-membered fused ring derivative AGTR2, ACSS2, ACSL3 TP53 4387/4885TSHR 2048/4885FFAR1 1037/4885
US-20180362543-A1 HIV REPLICATION INHIBITOR RTF2, REV1, PCNA TP53 2963/4885TSHR 4441/4885FFAR1 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.